Immunotherapy combo may extend Cancer-Free time after melanoma surgery
NCT ID NCT03313206
First seen Jan 21, 2026 · Last updated May 11, 2026 · Updated 11 times
Summary
This study tests whether giving immunotherapy (anti-PD1) before and after surgery, plus radiation, can help people with a rare head and neck melanoma stay cancer-free longer. About 60 adults with resectable tumors will receive the treatment and be followed for 2 years. The goal is to see if this approach improves disease-free survival compared to past results with surgery and radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK MUCOSAL MELANOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val De Marne, 94805, France
Conditions
Explore the condition pages connected to this study.